Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective studyBMC cancer, 2021-09, Vol.21 (1), p.1-1045, Article 1045 [Peer Reviewed Journal]COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-021-08766-9 ;PMID: 34556087Full text available |
|
2 |
Material Type: Article
|
Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participantsPLoS medicine, 2020-07, Vol.17 (7), p.e1003178 [Peer Reviewed Journal]COPYRIGHT 2020 Public Library of Science ;COPYRIGHT 2020 Public Library of Science ;2020 Larsson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Larsson et al 2020 Larsson et al ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1003178 ;PMID: 32701947Full text available |
|
3 |
Material Type: Article
|
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literaturePloS one, 2012-12, Vol.7 (12), p.e50946-e50946 [Peer Reviewed Journal]COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2012 Zhang et al 2012 Zhang et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0050946 ;PMID: 23284651Full text available |
|
4 |
Material Type: Article
|
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewPloS one, 2013-08, Vol.8 (8), p.e71583 [Peer Reviewed Journal]COPYRIGHT 2013 Public Library of Science ;COPYRIGHT 2013 Public Library of Science ;2013 Franciosi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Franciosi et al 2013 Franciosi et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0071583 ;PMID: 23936520Full text available |
|
5 |
Material Type: Article
|
Cancer statistics, 2022CA: a cancer journal for clinicians, 2022-01, Vol.72 (1), p.7-33 [Peer Reviewed Journal]2022 The Authors. published by Wiley Periodicals LLC on behalf of American Cancer Society ;2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. ;Copyright Wiley Subscription Services, Inc. Jan/Feb 2022 ;ISSN: 0007-9235 ;EISSN: 1542-4863 ;DOI: 10.3322/caac.21708 ;PMID: 35020204Full text available |
|
6 |
Material Type: Article
|
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerMolecular cancer, 2023-08, Vol.22 (1), p.1-138, Article 138 [Peer Reviewed Journal]COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-023-01827-6 ;PMID: 37596643Full text available |
|
7 |
Material Type: Article
|
PD-1 blockade inhibits osteoclast formation and murine bone cancer painThe Journal of clinical investigation, 2020-07, Vol.130 (7), p.3603-3620 [Peer Reviewed Journal]COPYRIGHT 2020 American Society for Clinical Investigation ;COPYRIGHT 2020 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jul 2020 ;2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci133334 ;PMID: 32484460Full text available |
|
8 |
Material Type: Article
|
Risk of second primary cancers after a diagnosis of first primary cancer: A pan-cancer analysis and Mendelian randomization studyeLife, 2023-11, Vol.12 [Peer Reviewed Journal]2023, Ruan, Huang et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023, Ruan, Huang et al 2023 Ruan, Huang et al ;ISSN: 2050-084X ;EISSN: 2050-084X ;DOI: 10.7554/eLife.86379 ;PMID: 37917154Full text available |
|
9 |
Material Type: Article
|
Cancer statistics, 2023CA: a cancer journal for clinicians, 2023-01, Vol.73 (1), p.17-48 [Peer Reviewed Journal]2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. ;Copyright Wiley Subscription Services, Inc. Jan/Feb 2023 ;ISSN: 0007-9235 ;EISSN: 1542-4863 ;DOI: 10.3322/caac.21763 ;PMID: 36633525Full text available |
|
10 |
Material Type: Article
|
Correction to: Managing Ibrutinib-Intolerant Patients With B-Cell MalignanciesThe oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e487-e487 [Peer Reviewed Journal]The Author(s) 2023. Published by Oxford University Press. 2023 ;COPYRIGHT 2023 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyad048 ;PMID: 36821849Full text available |
|
11 |
Material Type: Article
|
Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancerBMC endocrine disorders, 2024-01, Vol.24 (1), p.9-5, Article 9 [Peer Reviewed Journal]2024. The Author(s). ;COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1472-6823 ;EISSN: 1472-6823 ;DOI: 10.1186/s12902-024-01539-y ;PMID: 38212751Full text available |
|
12 |
Material Type: Article
|
Correction to: Cancer incidence in Khyber Pakhtunkhwa, Pakistan, 2020BMC public health, 2023-10, Vol.23 (1), p.1-1974, Article 1974 [Peer Reviewed Journal]COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2458 ;EISSN: 1471-2458 ;DOI: 10.1186/s12889-023-16888-x ;PMID: 37821858Full text available |
|
13 |
Material Type: Article
|
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacyJournal of hematology and oncology, 2019-05, Vol.12 (1), p.54-54, Article 54 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1756-8722 ;EISSN: 1756-8722 ;DOI: 10.1186/s13045-019-0738-1 ;PMID: 31151482Full text available |
|
14 |
Material Type: Article
|
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupBMC cancer, 2019-05, Vol.19 (1), p.494-494, Article 494 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-019-5675-4 ;PMID: 31126258Full text available |
|
15 |
Material Type: Article
|
Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMTMolecular cancer, 2019-03, Vol.18 (1), p.40-40, Article 40 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-019-0959-5 ;PMID: 30866952Full text available |
|
16 |
Material Type: Article
|
TIM-3, a promising target for cancer immunotherapyOncoTargets and therapy, 2018-01, Vol.11, p.7005-7009 [Peer Reviewed Journal]COPYRIGHT 2018 Dove Medical Press Limited ;COPYRIGHT 2018 Dove Medical Press Limited ;2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 He et al. This work is published and licensed by Dove Medical Press Limited 2018 ;ISSN: 1178-6930 ;EISSN: 1178-6930 ;DOI: 10.2147/ott.s170385 ;PMID: 30410357Full text available |
|
17 |
Material Type: Article
|
Correction to: The function and mechanisms of action of circular RNAs in Urologic CancerMolecular cancer, 2023-04, Vol.22 (1), p.73-73, Article 73 [Peer Reviewed Journal]COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-023-01774-2 ;PMID: 37095498Full text available |
|
18 |
Material Type: Article
|
Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathwayMolecular cancer, 2019-02, Vol.18 (1), p.20-20, Article 20 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-018-0935-5 ;PMID: 30717751Full text available |
|
19 |
Material Type: Article
|
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancerMolecular cancer, 2019-03, Vol.18 (1), p.68-68, Article 68 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-019-0972-8 ;PMID: 30927911Full text available |
|
20 |
Material Type: Article
|
Exosome-based immunotherapy: a promising approach for cancer treatmentMolecular cancer, 2020-11, Vol.19 (1), p.1-160, Article 160 [Peer Reviewed Journal]COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-020-01278-3 ;PMID: 33183286Full text available |